Organization
Shanghai Jiao Tong University Affiliated Sixth People’s Hospital
7 abstracts
Abstract
ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma.Org: Musculoskeletal Tumor Center, Peking University People's Hospital, Tianjin Medical University Cancer Institute and Hospital, Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.Org: AstraZeneca, Winship Cancer Institute, Department of Thoracic Oncology, Kanagawa Cancer Center, Kanagawa Cancer Center, Cancer Center Clínica Universidad de Navarra, Madrid, Spain,
Abstract
Interim results from a prospective multicenter phase II trial of stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC trial).Org: Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
Effect of blocking CD96 on CD8+ T cell–mediated elimination of tumor dormancy.Org: Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
Predictive value of positive lymph node ratio in patients with locally advanced gastric remnant cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Renji Hospital Shanghai Jiaotong University School of Medicine, School of Medicine, Zhejiang University, Hangzhou, China, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Phase 2 study of telisotuzumab vedotin (Teliso-V) monotherapy in patients with previously untreated MET-amplified locally advanced/metastatic non-squamous non-small cell lung cancer (NSQ NSCLC).Org: AbbVie Inc., North Chicago, IL, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
Personalized circulating tumor DNA (ctDNA) analysis in predicting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC).Org: Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,